Magnesium Supplementation in Type II Diabetes
- Conditions
- Effect of Magnesium in Diabetes
- Registration Number
- NCT03002545
- Lead Sponsor
- Protina Pharmazeutische GmbH
- Brief Summary
This study aims to determine how a 12-week magnesium supplementation with 400 mg magnesium from organic magnesium citrate affects blood glucose control and insulin resistance within patients with type 2 diabetes (HbA1c\> 6%) and how the expression of certain Mg-sensitive transporting genes is affected .
- Detailed Description
The examinations are carried out in 50 subjects aged 20-80 years with existing type 2 diabetes (HbA1c\> 6%). The target parameters are determined in the blood. Blood sampling takes place at confinement, after 6 weeks and at the end of the study (week 12). In addition, blood pressure is determined and general health condition of each subject is recorded by a standardized questionnaire (SF-36).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Type II Diabetics (HbA1c > 6%)
- pregnancy, lactation
- persons with severe renal impairment (glomerular filtration rate <30 ml / min)
- use of insulin, oral antidiabetic drugs, diuretics, antacids or proton pump inhibitors within 4 weeks prior to study start and during the study
- intake of vitamin supplements, dietary supplements, mineral products or possibly enriched foods containing Magnesium within 4 weeks before study start and during the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method questionnaire SF-36 12 weeks questionnaire is used to assess the physiological health Status of patients
blood sampling 12 weeks measurement of type II Diabetes relevant Parameters including Glucose, HbA1c, HOMA-IR, magnesium-sensitive gene expression
blood pressure measurement 12 weeks measurement of blood pressure
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
St. Anna Hospital
🇩🇪Herne, Germany
St. Anna Hospital🇩🇪Herne, Germany